LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market.
Announces, that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a secondary public offering of its American Depositary Shares (“ADSs”), each of which will represent 65 of the Company’s ordinary shares of no par value each (“Ordinary Shares”) in the United States (the “Offering”).
All ADSs to be sold in the Offering will be offered by OKYO. The number of ADSs to be offered and the price range for the Offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether, or when, the Offering may be completed or as to the actual size or terms of the Offering. The Offering will be conducted within the parameters of the authorities conferred upon OKYO by its shareholders at its annual general meeting on 7 September 2022.
Upon completion of the Offering, OKYO’s Ordinary Shares will continue to be admitted to listing on the standard segment of the Official List of the Financial Conduct Authority (“FCA”) (“Standard Listing”) and to trading on the main market for listed securities (“Main Market”) of London Stock Exchange plc (“LSE”) under the symbol “OKYO” and on the NASDAQ under the symbol “OKYO”.
ThinkEquity is acting as the sole bookrunning manager for the Offering. The Offering will be made only by means of a prospectus, which, for the avoidance of doubt, will not constitute a “prospectus” in any member state of the European Economic Area (“EEA”) for the purposes of Regulation (EU) 2017/1129 (as amended) (the “EU Prospectus Regulation”) or in the UK for the purposes of the EU Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended) (the “UK Prospectus Regulation”). In order to admit the underlying Ordinary Shares to a Standard Listing and to trading on the Main Market of the LSE, OKYO has prepared a prospectus for the purposes of the UK Prospectus Regulation (the “UK Admission Prospectus”). The UK Admission Prospectus is being reviewed by the FCA as the competent authority in the UK and will be published as part of the completion of the Offering. However, no offer of securities to the public is being made in any member state of the EEA or the UK.
When available, copies of the preliminary prospectus relating to and describing the terms of the Offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [email protected] Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the U.S. Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 134 under the Securities Act.
For the purposes of UK MAR, the person who arranged the release of this information is Gary S. Jacob, Chief Executive Officer.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF UNITED KINGDOM (“UK”) DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS ( SI 2019/310 ) (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
For further information, please contact:
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
+44 (0)20 7495 2379
Gabriele Cerrone, Non-Executive Chairman
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned